Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Down 39.2% in February

Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 567,600 shares, a drop of 39.2% from the February 13th total of 934,300 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 955,300 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Investors Weigh In On Tiziana Life Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Zhang Financial LLC grew its stake in shares of Tiziana Life Sciences by 34.3% in the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock worth $65,000 after acquiring an additional 23,800 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Tiziana Life Sciences by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after acquiring an additional 27,041 shares during the last quarter. Bison Wealth LLC acquired a new stake in shares of Tiziana Life Sciences in the fourth quarter worth $30,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Tiziana Life Sciences in the third quarter worth $864,000.

Tiziana Life Sciences Price Performance

NASDAQ:TLSA opened at $1.57 on Monday. Tiziana Life Sciences has a 12 month low of $0.41 and a 12 month high of $1.91. The company’s 50 day moving average is $0.92 and its 200-day moving average is $0.92.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.